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Assessment of the potential of growth factors for localized
alveolar ridge augmentation: a systematic review
Abstract
OBJECTIVE: To systematically assess the literature regarding the clinical, histological, and
radiographic outcome of bone morphogenetic proteins (BMP-2, BMP-7), growth/differentiation factor-5
(GDF-5), platelet-derived growth factor (PDGF), and parathyroid hormone (PTH) for localized alveolar
ridge augmentation. MATERIAL AND METHODS: Five separate Medline searches were performed in
duplicate for human and animal studies, respectively. The primary outcome of the included studies was
bone regeneration of localized alveolar ridge defects or craniofacial defects. RESULTS: In six human
studies, BMP-2 affected local bone augmentation with increasing volume for higher doses. A majority
(43 of 45) of animal studies using BMP-2 showed a positive effect in favour of the growth factor (GF).
In six of eight studies, a positive effect was associated with the use of BMP-7. Only one animal study
was included for GDF-5 revealing statistically significantly higher bone volume. Regarding PDGF,
statistically significantly higher bone volume was observed in five of 10 included studies. Four animal
studies using PTH revealed statistically significantly more bone regeneration compared with controls.
CONCLUSIONS: Differing levels and quantity of evidence were noted to be available for the GFs
evaluated, revealing that BMP-2, BMP-7, GDF-5, PDGF, and PTH may stimulate local bone
augmentation to various degrees. Human data for the potential of rhBMP-2 are supportive.
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Abstract 
Objective: To systematically assess the literature regarding the clinical, histological and 
radiographical outcome of bone morphogenic proteins (BMP-2, BMP-7), growth/differentiation 
factor 5 (GDF-5), platelet-derived growth factor (PDGF), and the parathyroid hormone (PTH) for 
intraoral bone augmentation in humans and animals.   
Methods: Five separate Medline searches were performed in duplicate for human and animal 
studies, respectively. The primary outcome of the included studies was local bone augmentation.  
Results: The 10 electronic searches identified a total of 3634 titles, out of which 637 were 
obtained as abstracts. From full-text articles a total of 74 studies were included in the analyses. No 
human studies meeting the inclusion criteria were found for BMP-7, GDF-5, PTH, and PDGF. 
However, 6 studies reported bone regeneration with BMP-2 in humans. The applied factor affected 
local bone augmentation with increasing volume for higher BMP-2 doses. Compared to controls, the 
effect of BMP-2 revealed heterogeneity. A majority (43 of 45) of the animal studies using BMP-2 
showed a positive effect in favor of the growth factor. In 6 of 8 studies, a positive effect was 
associated with the use of BMP-7. Only one animal study was included for GDF-5 revealing 
statistically significantly higher bone volume. Regarding PDGF, statistically significantly higher 
bone volume was observed in 4 studies, whereas 4 studies reported no significant differences. Four 
animal studies using PTH revealed statistically significantly more bone regeneration compared to 
control groups.  
Conclusions: The present literature revealed that BMP-2, BMP-7, GDF-5, PDGF and PTH 
might stimulate local bone augmentation to various degrees. To define clinical indications for there 
application randomized controlled clinical trials are desperately needed comparing the effects of 
growth factors with standard of care in challenging intraoral bone defects.  
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Introduction 
The ability to perform intraoral bone augmentation has expanded the treatment options in 
implant dentistry. Various methods have been described to augment bone prior to or in combination 
with implant installation: (a) grafting with autogenous bone from both intra-oral and extra-oral donor 
sites (Misch et al. 1992; Raghoebar et al.1996), (b) guided bone regeneration (GBR), which allows 
spaces maintained by barrier membranes to be filled with bone (Dahlin et al. 1988; Kostopoulos & 
Karring 1994; Nyman & Lang 1994; Hämmerle et al. 1996), (c) distraction osteogenesis, a gradual, 
controlled displacement of surgically created fractures (Ilizarov 1989a; Ilizarov 1989b), and (d) 
tissue engineering, which is a multidisciplinary field that aims to repair or even regenerate tissue and 
organs (Arosarena 2005).  
Among these methods, GBR is one of the best-documented techniques for intraoral bone 
augmentation (for a review see Hämmerle & Jung 2003). However, GBR has different clinical 
limitations like the long treatment time, limited predictability for vertical bone augmentation (Simion 
et al. 1994), risk of infection subsequent to membrane exposure (Chiapasco et al. 1999), and 
technique sensitivity. In order to overcome some of these difficulties research has been driven 
towards the use of bioactive molecules to induce local bone formation (Urist 1965; Reddi et al. 
1987). A variety of growth factors including bone morphogenic proteins (BMPs), platelet-derived 
growth factor (PDGF), and peptides of the parathyroid hormone (PTH) have been tested for local 
bone regeneration. 
BMPs belonging to the TGF-BB superfamily are most often named when it comes to growth 
factor enhanced bone healing. Among the more than 30 identified BMPs, only a small number 
(BMP-2, BMP-4, BMP-7, BMP-9) seem to have osteoinductive functions (Cheng et al. 2003). 
Several human clinical trials have been published using BMP-2 for bone regeneration (Boyne et al. 
1997; Cochran et al. 2000; Jung et al. 2003). These studies showed superior results using BMP-2 
when compared to respective control groups. On the other hand, the selection of the carrier seems to 
play an important role in terms of bone regeneration with the use of growth factors (Sigurdsson et al. 
1996; Wikesjo et al. 1998). Research is demanded as collagen sponges used as carrier material lack 
mechanical stability (Barboza et al. 2000).  
Human cDNA BMP-7 (osteogenic protein-1; OP-1) was cloned in 1990. Recombinant human 
OP-1 (rhOP-1) was later developed and was shown to induce new bone formation comparable to 
natural bovine osteogenic protein (Sampath et al. 1992). Based on favorable animal and clinical 
results concerning the osteogenic potential of rhBMP-7 (Friedlaender et al. 2001; Chen et al. 2002; 
  
 4 
Makino et al. 2005), rhBMP-7 was commercialized (Stryker, Kalamazoo, MI, USA). In 2001, 
rhBMP-7 was approved in Australia and Europe for clinical use in non-unions. Compared to 
autografts, which necessitate a second surgical site, and therefore increase operating time, risk of 
morbidity, patient pain, and recovery, the use of BMP-7 was shown to be superior, especially in 
patients with known risk factors (Govender, et al. 2002; Kanayama, et al. 2006; Ronga, et al. 2006).  
The growth/differentiation factors (GDFs) belong to the class of BMP signaling molecules. 
Several mouse models exist with functional null mutations in GDFs leading to specific skeletal tissue 
phenotypes. These phenotypes allow studying the function of these GDFs (for an overview see Mikic 
2004).  It has been shown, that GDFs play an important role in the development and regeneration of 
tendon, cartilage, bone, and skin (Wolfman, et al. 1997; Storm & Kingsley 1999; Mikic, et al. 2002; 
Chhabra, et al. 2003). Recent publications have been focused on the use of GDF-5 for local bone 
augmentation in the field of dentistry (Kuniyasu et al. 2003; Nakamura et al. 2003; Yoshimoto et al. 
2006).  
PDGF is a well-characterized tissue growth factor that has been used in various animal and 
human studies (Camelo et al. 2003; Nevins et al. 2003; Nevins et al. 2005; Park et al. 1998; 
Giannobile et al. 1996). It was first introduced in dentistry in the field of periodontology and has 
shown to be mitogenic and chemotactic for periodontal ligament cells, with the additional effect of 
promoting regeneration of bone, ligament, and cement (Lynch et al. 1991; Lynch et al. 1989). Recent 
publications have shown, that rhPDGF-BB combined with a deproteinized bovine block without 
placement of a barrier membrane, had the potential to regenerate significant amounts of new bone in 
severe mandibular ridge defects in an animal model (Simion et al. 2006), as well as in patients 
(Simion et al. 2007). However, in contrast, another study showed, that the combination of rhPDGF-
BB with a bone substitute material (deproteinized bovine bone mineral granules; DBBM) resulted in 
limited bone formation compared to DBBM alone (Lioubavina-Hack et al. 2005a).  
In addition to growth factors, the use of peptides of the parathyroid hormone (PTH) have also 
been investigated for modulating bone healing. PTH has been shown to have multiple anabolic 
effects on both cancellous and cortical bone (Rizzoli et al. 1992; Whitfield et al. 2000). Presently, 
PTH is used for systemic treatment of osteoporosis. Clinical trials have shown this therapy to be 
effective in increasing bone density (Neer et al. 2001). Few studies evaluated the use of PTH as an 
adjunctive factor for local bone augmentation (Skripitz et al. 2000; Jung et al. 2007a&b).  
To date, there is limited evidence for the application of growth factors for local bone 
augmentation in dentistry. The aim of the present review was therefore, to systematically assess the 
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literature regarding the clinical, histological and radiographical outcome of BMP (BMP-2, BMP-7, 
GDF-5), PDGF, and PTH for intraoral bone augmentation procedures in humans and animals.   
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Material and Methods 
Search strategy 
Five separate Medline (PubMed) searches were performed in duplicate for human and animal 
studies, respectively. The articles were published from 1966 up to September 2007 in the Dental 
literature. All searches were limited to the English and German languages. The following search 
terms were selected: „*bone morphogenic protein* (*bmp*)“ (search 1 and 2 for bmp-2), „platelet 
derived growth factor* (*pdgf*)“ (search 3 and 4), *parathyroid hormone* (*pth*)“ (search 5 and 6), 
„osteogenic protein* (*op*)“, or  „*bone morphogenic protein* (*bmp*)“ (search 7 and 8 for bmp-7, 
op-1), *growth/differentiation factor* (*gdf*)“ (search 9 and 10). All these search terms were 
meshed with “*bone*”, and “*regeneration*”. 
Every search was complemented by manual searches of the reference list of all selected full-
text articles. Additionally, full text articles of reviews published between January 2005 and 
September 2007 were obtained. An additional hand search was performed searching for relevant 
studies by screening these reviews.  
Inclusion criteria 
The applied inclusion criteria were different for preclinical and clinical studies. For the 
preclinical studies only controlled studies were included. The primary outcome of the experiments 
had to be local bone augmentation. At least 5 animals had to be included. A follow-up period was not 
defined. The reported treatment outcomes had to include at least 1 of the following parameters: 
clinical, radiographic, or histological effects of the growth factor (GF) or the control(s).  
For the human studies, any prospective cohort was selected, which included at least 10 
patients. The patients had to be followed for at least 3 months. The reported treatment outcomes were 
considered to be either clinical, radiographic, or histological. Again, the primary outcome of the 
studies had to be local bone augmentation.  
Exclusion criteria 
Studies not meeting all inclusion criteria were excluded from the review. Publications were 
also excluded if the primary outcome was not local bone augmentation. Studies dealing with the 
following topics were excluded: in vitro studies, studies using gene therapy, studies with focus on 
periodontal regeneration, studies reporting systemic treatment outcomes, craniofacial surgery for 
total or partial reconstruction of mandibles/maxillas, cleft lip and palate surgeries, distraction 
osteogenesis, or orthopedic surgeries. 
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Selection of studies 
Titles derived from this broad search were independently screened by 2 authors (RJ, DT) 
based on the inclusion criteria. Disagreements were resolved by discussion. Cohen’s Kappa-
coefficient was used as a measure of agreement between the 2 readers. Following this, abstracts of all 
titles agreed on by both authors were obtained, and screened for meeting the inclusion criteria. If no 
abstract was available in the database, the abstract of the printed article was used. The selected 
articles were then obtained in full text. If title and abstract did not provide sufficient information 
regarding the inclusion criteria, the full report was obtained as well. Again, disagreements were 
resolved by discussion. 
Finally, the selection based on inclusion/exclusion criteria was made for the full text articles. 
For this purpose Material and Methods, and Results of these studies were screened. This step was 
again carried out independently by 2 readers. Disagreements were resolved by discussion.  
Data extraction 
The data were independently extracted by 2 reviewers using data extraction tables. Any 
disagreements were resolved by discussion aiming for consensus. For clinical studies, information on 
the following parameters was extracted: authors, year of publication, study design, number of 
patients, mean age of patients, follow-up period, applied dose of growth factor, carrier system, 
control group, type and dimension of defect, decrease in defect height/increase in bone height/width, 
newly formed bone, and new bone density. For all categories, obtained data for preclinical studies 
included: authors, year of publication, animal species, number of animals, follow-up period, applied 
dose of growth factor, carrier system, control group(s), type and dimension of defect, percentage of 
defect fill, bone-to-implant contact, regenerated bone area, regenerated bone height/width, bone 
mineral density, and radiopacity of regenerated bone area. 
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Results 
Study characteristics 
The 10 electronic searches identified a total of 132, 145, 482, 774, 594, 267, 16, 36, 433, and 
755 titles for “PDGF humans”, “PDGF animals”, “BMP-2 humans”, “BMP-2 animals”, “PTH 
humans”, “PTH animals”, “GDF-5 humans”, “GDF-5 animals”, “BMP-7 humans”, and “BMP-7 
animals”, respectively (for details refer to Fig. 1-10).  From assessing the titles, 2997 were excluded 
(inter-reader agreement k=0.87 ± 0.01). The resulting number of abstracts obtained was 43, 50, 95, 
242, 36, 45, 3, 4, 30, and 89 for “PDGF humans”, “PDGF animals”, “BMP-2 humans”, “BMP-2 
animals”, “PTH humans”, “PTH animals”, “GDF-5 humans”, “GDF-5 animals”, “BMP-7 humans”, 
and “BMP-7 animals”, respectively. Screening these abstracts, 510 were excluded. Five, 16, 10, 54, 
4, 8, 1, 4, 7, and 20, respectively, full text articles were obtained. Finally, 0, 9, 6, 45, 0, 4, 0, 1, 0, and 
9 articles, respectively, met the inclusion criteria. 
Exclusion of studies 
The main reasons for excluding studies (n=19) after the full text was obtained were: an 
insufficient number of animals/patients, no control group (preclinical studies), and no reported or 
insufficient clinical, radiographic, or histological treatment outcomes (only descriptive presentation 
of results). One study (Cochran et al. 2000) was excluded, since it reported on data from an earlier 
publication (Boyne et al. 1997). An additional study (Terheyden et al. 2001) was excluded, since the 
data were congruent with another publication (Terheyden et al. 1999). 
Included studies 
The 74 studies that met the inclusion criteria are presented in Tables 1-6. Table 1 represents 
data for human studies using BMP-2. Tables 2-6 refer to preclinical studies for all growth factors 
(BMP-2, -7, GDF-5, PDGF, and PTH). For all growth factors other than BMP-2, no human studies 
were found to meet the inclusion criteria.  
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Human studies  
Bone morphogenic protein-2 (BMP-2) 
Six studies reporting on bone augmentation with BMP-2 were included in the analysis. Four 
studies were designed as randomized controlled clinical trials (RCT), and two as prospective cohort 
studies. A total number of 183 patients were treated with growth factors for local intraoral bone 
regeneration. The mean age of the patients was 52 years. The mean follow-up period was 4.3 (4 to 6) 
months. BMP-2 was always locally administered. The applied dose of BMP-2 ranged from 0.5 to 
1.75 mg/mL, or 0.12 to 3.4 mg/patient, respectively. Two different carrier systems were used for the 
application of BMP-2. Five studies used an absorbable collagen sponge (ACS), whereas in one study 
the growth factor was applied in a demineralized bovine bone matrix (DBBM) (Jung et al. 2003). 
The type of local bone augmentation encompassed sinus floor augmentations (Boyne et al. 1997, 
Boyne et al. 2005), preservations of extraction socket (Howell et al. 1997, Bianchi et al. 2004; 
Fiorellini et al. 2005), augmentation of localized ridge defects (Howell et al. 1997), and lateral ridge 
augmentation in combination with simultaneous implant placement (Jung et al. 2003). Due to the 
heterogeneity of the studies (various indications, RCT or cohort) no meta-analysis of the outcomes 
was performed. 
Treatment outcomes 
Patient-based treatment outcomes on local bone augmentation retrieved from 6 included 
studies are presented in Table 1.  
(1) Bone height increase / Defect size decrease 
An increase in bone height ranging from 6.8 to 10.2mm (for sinuslift procedures, lateral ridge 
augmentations), and a change in bone height between -2.1 and 2.4 mm (for ridge 
preservations/extraction socket augmentations) were reported for sites treated with BMP-2. Four 
RCTs included at least one control group without the application of the growth factors (Jung et al. 
2003, Bianchi et al. 2004; Boyne et al. 2005; Fiorellini et al. 2005). In one of these studies, data for 
bone height were presented, and the average gain in bone height was 11.3 mm for control sites, and 
9.5 mm for test sites with BMP-2, respectively (Boyne et al. 2005). Two studies reported on the 
treatment outcome measured as a decrease in defects size (Jung et al. 2003) or change in bone height 
(Fiorellini et al. 2005). The effect of the growth factor varied and was different in each study. The 
dose of the applied factor seemed to have an impact on the treatment outcome, with higher local 
bone regeneration for higher BMP-2 doses (Bianchi et al. 1994; Howell et al. 1997; Boyne et al. 
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2005), and less decrease in bone height at extraction socket sites (Fiorellini et al. 2005). Compared to 
controls without growth factors, the effect of BMP-2 revealed substantial variability. Data from one 
study showed no statistically significant effects of BMP- 2 on the treatment outcome in a lower dose, 
but a statistically significant positive effect in a higher dose (Fiorellini et al. 2005). Another study 
found no statistically significant differences to the control group regarding the increase in ridge 
height, and even less ridge width with the use of BMP-2 (Boyne et al. 2005). Only one RCT reported 
a positive effect compared to the control group, when the factor was applied for lateral ridge 
augmentation (Jung et al. 2003).  
(2) New bone formation 
Three studies reported on new bone formation either as a percentage of the original defect 
(Jung et al. 2003), as gain in bone volume (Bianchi et al. 2004), or as new bone density (Boyne et al. 
2005). The effect of applying BMP-2 varied between statistically significant less new bone density 
with the factor (Bianchi et al. 2004), statistically not significantly more bone formation in a lower 
dose (Boyne et al. 2005), and statistically significantly more newly formed bone with a higher dose 
(Boyne et al. 2005) compared to control groups. One study reported a positive but not statistically 
significant effect of BMP-2 regarding the amount of newly formed bone (37 ± 11.2%) compared to 
the control group (30 ± 8.9%) (Jung et al. 2003). However, statistically significantly more mature 
lamellar bone (76 ± 14.4% vs. 56 ± 18.3%) and statistically significantly more bone to graft contact 
(57 ± 16.2% vs. 30 ± 22.6%) was detected at the BMP-2 treated sites compared to the sites grafted 
without BMP-2. 
 
Animal studies 
Since a large heterogeneity exists within the included animal studies, the obtained data for all 
growth factors were not further analyzed and, hence, presented in a descriptive manner in Tables 2-6. 
Bone morphogenic protein-2 (BMP-2) 
Table 2 represents data retrieved from animal studies using BMP-2. A total number of 45 
preclinical studies fulfilled the inclusion criteria. The following animal species were used: rats, 
rabbits, goats, mini-pigs, and dogs. The type of defect prepared and treated for local bone 
augmentation encompassed critical-size defects in the skull, mandibular defects, peri-implant defects, 
alveolar ridge augmentation, sinus lift procedures, extraction sockets, vertical ridge augmentation, 
alveolar periodontal defects for vertical ridge augmentation.  
  
 11 
Treatment outcomes 
Due to the large heterogeneity concerning animals species, type of defects, applied dose of 
BMP-2, carrier system, observation periods, treatment outcomes of these preclinical studies cannot 
be compared. The effect of the applied growth factor varies from study to study and even within the 
same study from time-point to time-point. In 43 of the 45 included studies at least at one time-point 
and compared to at least one control group a positive effect or even statistically significant 
differences were found in favor of using BMP-2. Only 2 studies were not able to show any positive 
effect using BMP-2 for local bone augmentation (Brandao et al. 2004; Liu et al. 2007).  
Bone morphogenic protein-7 (BMP-7) 
Table 3 represents data obtained from animal studies using BMP-7. Eight studies met the 
inclusion criteria. Rats, rabbits, baboons, and chimpazees were chosen as animal models. The type of 
defects encompassed extraction sockets, calvarial defects, and sinus augmentation procedures with or 
without simultaneous implant placement. 
Treatment outcomes 
As for BMP-2, these studies on BMP-7 could not be compared with each other due to 
substantial heterogeneity. In 6 studies (Ripamonti et al. 1996; McAllister et al. 1998; Terheyden et 
al. 1999; Ripamonti et al. 2001; Liu et al. 2006; Mhawi et al. 2007), a positive effect was associated 
with the use of BMP-7 at least at one time-point and compared to at least one control group. Only 2 
studies failed to show any positive effect of BMP-7 (Margolin et al. 1998; Springer et al. 2005).  
Growth/differentiation factor-5 (GDF-5) 
Table 4 shows data obtained from one included study (Poehling et al. 2005).  
Treatment outcomes 
500µg of rhGDF-5 were applied using ß-tricalciumphosphate (ß-TCP) as a carrier material in 
critical size defects in the Sprague-Dawley rats. The treatment outcome after an observation period 
of 6 weeks revealed statistically significant more bone formation compared to the control groups (ß-
TCP, bovine bone mineral (BBM), BBM plus collagen, BBM plus a synthetic peptide, and a sham-
operated site). 
Platelet-derived growth factor (PDGF) 
Nine studies met the inclusion criteria (Table 5). The surgeries were performed in rats, 
rabbits, and dogs. Calvarial defects, denuded mandibular ramus’, peri-implant defects, vertical bone 
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regeneration in the mandible, and local bone regeneration around immediate implants in fresh 
extraction sockets were used as models. 
Treatment outcomes 
Eight studies reported treatment outcomes on newly formed bone. Statistically significantly 
more bone volume was observed in 4 studies (Vikjar et al. 1997; Lee et al. 2000; Meraw et al. 2000; 
Lee et al. 2001). The remaining 4 studies reported no significant differences when using rhPDGF as 
growth factor, or even significantly less bone formation compared to the controls (Marden et al. 
1993; Stefani et al. 2000; Lioubavina-Hack et al. 2005a&b). Data regarding the bone-to-implant 
contact (BIC) were obtained from 2 studies (Meraw et al. 2000; Stefani et al. 2001). In one study 
(Meraw et al. 2000), the BIC was significantly higher at the test sites at 12 weeks. These data were 
different from the second study (Stefani et al. 2000) that showed a statistically significantly greater 
BIC at 3 weeks, but not for the later observation periods at 8 and 12 weeks. Only clinical treatment 
outcomes were reported in one study (Simion et al. 2006), Compared to the control group without 
PDGF (25%), more sites healed uneventfully using the growth factor (75%). No data on bone 
regeneration were reported in that study. 
Parathyroid hormone (PTH) 
Four studies met the inclusion criteria (Table 6). Two studies were performed in rats (Skripitz 
et al. 2000; Andreassen & Cacciafesta 2004), one study in rabbits (Jung et al. 2007a), and one in 
dogs (Jung et al. 2007b). The chosen defect models encompassed titanium cylinders (Skriptiz et al. 
2000; Jung et al. 2007a), or critical size defects (Andreassen & Cacciafesta 2004), both on the skull, 
and peri-implant defects (Jung et al. 2007b).  
Treatment outcomes 
All 4 studies reported different treatment outcomes and hence, could not be compared. 
Compared to the controls, statistically significantly more new bone volume was observed for the 
tested PTH independently of the animal model. 
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Discussion 
The present systematic review assessed the potential of BMP-2, BMP-7, GDF-5, PDGF, and 
PTH for intraoral bone augmentation. In humans, only 6 studies investigating BMP-2 met the 
inclusion criteria and demonstrated generally a positive, but heterogeneous effect on local bone 
augmentation. In animals, a total of 67 included studies reported about BMP-2, BMP-7, GDF-5, 
PDGF, and PTH in various animal models and with various protocols. Although inconsistent results 
have been reported, the majority of the studies demonstrated statistically significantly more bone 
formation compared to control treatments without growth factors.  
Different growth factors are now on the way to enter clinical practice in dentistry. Hence, it is 
of utmost importance to systematically assess the effect of the growth factors on the healing of 
intraoral bone defects. The present electronic search identified a total of 3634 titles for the 
application of growth factors. However, only 4 randomized controlled clinical trials (RCTs) on 
BMP-2 were available for analysis. No human RCT for BMP-7, GDF-5, PDGF and PTH could be 
found. This in turn means, that the clinical documentation of the effect of growth factors for the 
application in the oral cavity is sparse. Hence, there is a need for further randomized controlled 
clinical trials using growth factors for intraoral bone augmentation in well defined clinical 
indications.  
Bone morphogenic protein-2 (BMP-2) 
Out of the six included human studies, five applied BMP-2 in an absorbable collagen sponge 
(ACS). All of these studies have investigated BMP-2 in bone defects, which are considered to be 
self-containing (i.e. sinus floor and extraction sockets). While it is recognized that collagen is one of 
the best researched carrier material, different animal studies have documented inadequate bone 
regeneration when collagen is used alone as a bone graft substitute (Barboza et al. 2000; Howell et al 
1997). Increased regeneration volume has been shown when collagen was combined with grafting 
materials (Miranda et al. 2005; Arosarena & Collins et al. 2005a). Only one clinical study has tested 
BMP-2 applied with grafting material (demineralized bovine bone matrix) for lateral bone 
augmentation (Jung et al. 2003). There is a lack of clinical data comparing the use of grafting 
materials over the use of collagen as carrier material for BMP-2 in non self-containing defects. 
Besides the carrier material the dosage seems also to play an important role for the successful 
application of BMP-2. Three clinical studies have investigated two different doses for BMP-2 
(Bianchi et al. 2004; Boyne et al. 2005; Fiorellini et al. 2005). It was demonstrated that the higher 
dosage reveals better results. However, the dosage applied in these clinical studies are several orders 
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of magnitude higher than naturally occurring BMP-2 concentrations (Urist et al. 1983). In order to 
overcome some of these difficulties a variety of preclinical studies are testing new optimized carrier 
systems to decrease the dosage of BMP-2 (Jung et al. 2008). 
It is concluded from the present literature that BMP-2 has been extensively tested in 
preclinical models revealing generally positive effects on local bone regeneration. Future studies 
should aim for randomized controlled clinical trials to treat challenging intraoral bone defects. 
Bone morphogenic protein-7 (BMP-7, OP-1) 
No clinical study was found using BMP-7 for intraoral local bone regeneration. The majority 
of the animal studies have used collagen as carrier material. Only two studies have used grafting 
materials as carrier system (Ripamonti et al. 2001; Terheyden et al. 1999).  
Five out of 8 included animal studies reported about the percentage of newly formed bone 
evaluated by histomorphometric measurements (Margolin et al. 1998; Ripamonti et al. 1996; 
McAllister et al. 1998; Ripamonti et al. 2001; Mhawi et al. 2007). Only one study in chimpanzee 
could not show a statistical significant difference compared to the control treatments without BMP-7 
(Margolin et al. 1998).  The remaining studies revealed statistically significant more newly formed 
bone compare the to control sites. However, in two studies only the higher dosage was able to 
increase the amount of newly formed bone significantly (McAllister et al. 1998; Ripamonti et al. 
2001).  
It can be concluded that BMP-7 applied by collagen or grafting materials was able to 
stimulate bone regeneration in different animal models. Future research should be directed towards 
randomized controlled clinical trials.  
Growth/differentiation factor-5 (GDF-5) 
Very little data is available for the use of GDF-5 in local bone augmentation. Only one study 
performed in rats was included in the present review (Poehling et al. 2005). It was demonstrated that 
GDF-5 significantly increased the amount of newly formed bone in critical sized calvarial defects 
compared to augmenting with standard grafting techniques (e.g. demineralized bovine bone matrix, 
DBBM). Wound healing in the control groups was mainly characterized by the formation of loose 
fibroconnective tissue and only limited bone formation at the defect margins. These observations are 
not in agreement to other animal studies using DBBM for bone regeneration (Thaller et al. 1994; 
Donos et al. 2004).  
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Due to the fact that only one study with one animal model, one concentration, and one time 
point investigated GDF-5 for intraoral bone augmentation no conclusions can be drawn. Further 
preclinical research is needed in order to understand the effect of GDF-5. 
Platelet derived growth factor (PDGF) 
Nearly fifty percent of all included animal studies investigating PDGF for intraoral bone 
augmentation were not able to show a significant effect compared to control treatments without 
PDGF. These limited results are in contrast to a recent human pilot study using PDGF for three-
dimensional ridge augmentation (Simion et al. 2007). It was demonstrated in 2 patients, that 
rhPDGF-BB combined with a deproteinized bovine bone block without the placement of a barrier 
membrane, had the potential to regenerate significant amounts of new bone in severe mandibular 
ridge defects.  
In the past, PDGF has mainly been tested for the treatment of periodontal defects (Lynch et 
al. 1991; Nevins et al. 2005). In a 24-month prospective randomized controlled clinical trial the 
combination of rhPDGF-BB and beta-tricalcium phosphate (TCP) was evaluated in the treatment of 
periodontal defects (Nevins et al. 2005). They showed a significant gain in clinical attachment level 
and significantly greater radiographic linear bone gain and percent defect fill compared to sites that 
received bone substitute with buffer. The controversial results using PDGF for either periodontal 
defects or bone defects might be explained by the fact that PDGF has been shown to be mitogenic 
and chemotactic for periodontal ligament cells but not osteoinductive (Lynch et al. 1989; Lynch et al. 
1991). Hence, the stimulating effect on osteoblasts might be limited. 
Based on the data of 9 animal studies, it can be concluded that PDGF has an unpredictable 
and limited effect on intraoral bone regeneration. Future research with new carrier materials may 
open additional indications. 
Parathyroid hormone (PTH) 
A limited number of studies investigated the use of peptide fragment of the parathyroid 
hormone (PTH1-34) for local bone regeneration (Andreassen & Cacciafesta 2004; Jung et al. 
2007a&b). While PTH has been shown to have a substantial beneficial effect in the systemic 
treatment of osteoporosis, its use for the treatment of local bone defects is relatively new. The 4 
included studies revealed all a statistically significant benefit compared to control treatments without 
using PTH. Two of the studies have administrated PTH by intermittent subcutaneous injections 
(Andreassen & Cacciafesta 2004; Skriptiz et al. 2000) and 2 by local application of the PTH peptide 
(Jung et al. 2007a&b). Replacement of intermittent systemic injections of PTH by local release of the 
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peptide would be beneficial regarding dosage and patient comfort. Newly developed carrier systems, 
like polyethylene-glycol (PEG), have been designed for local presentation of growth factors and 
peptides (Lutolf et al. 2003; Jung et al. 2007b). It was demonstrated that the PEG carrier system was 
able to control the release of growth factors (Lutolf et al. 2003). This might be especially important 
for the local administration of PTH for the treatment of intraoral bone defects. 
It can be concluded that a 34 amino acid peptide of the PTH is an interesting candidate for the 
treatment of local bone defects. However, future research is mandatory in order to better understand 
the way of action of the PTH for the therapy of intraoral bone defects. 
Conclusion 
From the analysis of this systematic search of the literature it is evident that BMP-2, BMP-7 
(OP-1), GDF-5, PDGF and PTH may stimulate local bone augmentation to various amounts as 
documented by preclinical animal studies.  However, only the application of BMP-2 has been studied 
in clinical trials. Owing to the fact that various indications for local intraoral bone augmentation 
could benefit from the use of BMP-2 the performances of RCTs in well-defined indications is a 
prerequisite for the routine recommendation of BMP-2 in bone augmentation procedures. Moreover, 
it is obvious that growth factors should only be applied to challenging intraoral bone defects. 
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Table 1. BMP-2 humans. 
 
Author
year of 
publicatio
n
study 
design
number of 
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follow-up 
period
applied 
dose
carrier 
system control 1 control 2
type of 
defect
outcome 
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outcome 
test
outcome 
control 1
outcome 
control 2
effect of 
factor vs 
control 1 
effect of 
factor vs 
control 2 
outcome 
measure
outcome 
test
outcome 
control 1
outcome 
control 2
effect of 
factor vs 
control 1 
effect of 
factor vs 
control 2 
comments
:
Bianchi et 
al. 2004 RCT 20 53.2 4 months
0.75mg/m
l ACS ACS empty
extraction 
socket 
augmentat
ion
new bone 
volume 
(cm3) 0.106 0.084 0.104 ns ns
20 
patients 
from 
Fiorellini 
study
1.5mg/ml ACS ACS empty 0.192 0.084 0.104 s s
Boyne et 
al. 1997
cohort 
study 12 51 4 months
1.77 - 
3.4mg 
rhBMP-2 
/ patient ACS
sinusfloor 
augmentat
ion
ct scans 
bone 
height 
increase
8.51 ± 
4.13 mm
Boyne et 
al. 2005 RCT 48 4 months
0.75mg/m
l ACS bone graft
sinusfloor 
augmentat
ion
increase 
ridge 
height 
(mm) 9.5 11.3 ns
new bone 
density 
(mg/cc) 84 350 s (neg.)
implants 
later 
placed 
1.5mg/ml ACS bone graft 10.2 11.3 ns 134 350 s (neg.)
0.75mg/m
l ACS bone graft
increase 
ridge 
width 
(mm) 2 4.7 s (neg.)
1.5mg/ml ACS bone graft 2 4.7 s (neg.)
Fiorellini 
et al. 2005 RCT 80 47.4 4 months
0.75mg/m
l ACS ACS empty
extraction 
socket 
augmentat
ion
height 
change 
(mm)
-
0.62±1.39 -1.0±1.4
-
1.17±1.23 ns ns
no sign. 
difference
s in bone 
density
1.5mg/ml ACS ACS empty -0.02±1.2 -1.0±1.4
-
1.17±1.23 s s
Howell et 
al. 1997
cohort 
study 6 55 4 months
0.12-
0.88mg 
rhBMP-2 ACS
ridge 
preservati
on
bone 
height 
(mm)
0.32 ± 
1.25
dose 
dependent
positive 
for > 
0.15mg/m
l BMP-2
6 52 4 months
0.20-
1.75mg 
rhBMP-2 ACS
ridge 
augmentat
ion
change in 
bone 
height 
(mm)
0.16 ± 
2.16
Jung et al. 2003 RCT 11 53 6 months
1ml of 
0.5mg/ml 
rhBMP-2 DBBM
lateral 
ridge 
augmentat
ion
decrease 
in defect 
depth 
(mm) 6.8±2.7 5.4±2.2 ns
newly 
formed 
bone
37 ± 
11.2% 30 ± 8.9% ns
simultane
ous 
implant 
placementmineralize
d bone 
(%)
76 ± 
14.4%
56 ± 
18.3% s
DBBM in 
contact 
with bone
57 ± 
16.2%
30 ± 
22.6% s
Mean 
(range)
30.5 (11-
80)
51.92 
(47.4-55) 4.3 (4-6)
excluded:
Cochran 2000
recall and implant placement in 
augmented bone of previous 
study (Boyne et al. 1997)
Author
year of 
publicat
ion
numbe
r of 
animal
s
animal 
species
follow-
up 
period
applied 
dose
carrier 
system
control 
1
control 
2
control 
3
control 
4
type of 
defect 
outcome 
measure
outcome 
test
outco
me 
control 
1
outco
me 
contr
ol 2
outco
me 
contr
ol 3
outco
me 
contr
ol 4
effect 
of 
factor 
vs. 
control 
1
effect 
of 
factor 
vs. 
control 
2
effect 
of 
factor 
vs. 
control 
3
effect 
of 
factor 
vs. 
control 
4
outcom
e 
measur
e
outco
me test
outco
me 
control 
1
outco
me 
control 
2
outco
me 
control 
3
effect 
of 
factor 
vs. 
control 
1
effect 
of 
factor 
vs. 
control 
2
effect 
of 
factor 
vs. 
control 
3 comments
Arosarena 
& Collins 2005a 16
Sprague-
Dawley 6 weeks
100ul 
BMP + 
CHT
100ul 
BMP + 
hy
collage
n/HA/T
CP 
(CHT)
hyaluro
nic 
acid 
polyme
r (hy)
mandibu
lar full 
thicknes
s defect
new bone 
+ bone 
marrow 
(%) 24 19 11 12
s; for 
groups 
with 
bmp2
Arosarena 
& Collins 2005b 82
Sprague-
Dawley 8 weeks
0.01, 
0.1, 1, 
10ug 
BMP2 
or 
BMP4
hyaluron
ic acid 
polymer
hyaluro
nic 
acid 
polyme
r + 
growth 
factor 
dilution 
buffer empty
critical 
size 
defects 
mandibl
e
new bone 
(%) 14-30 21 9
ns but 
positiv
e
ns but 
positiv
e
Barboza et 
al. 2004 6
mongrel 
dogs
12 
weeks
0.4mg/m
l BMP-2
ACS + 
DMB + 
BMP
ACS + 
BioGla
ss  + 
BMP
ACS + 
BMP-2 empty
alveolar 
ridge 
augment
ation 
(chronic 
defects)
clinical 
measurem
ents ridge 
width 
change 
(mm) 4.4 4.6 2.2 0.1
positiv
e 
versus 
control
positiv
e 
versus 
control
positiv
e 
versus 
control
Brandao et 
al. 2002 45
Wistar 
rats
1, 3, and 
6 weeks 3mg HA HA
no 
treatme
nt
extractio
n 
sockets
bone 
tissue 
volume 
(1w) 22.9 25 25 ns ns
bone 
tissue 
volume 
(3w) 28.9 37.4 52.5
s 
(negati
ve)
s 
(negati
ve)
bone 
tissue 
volume 
(6w) 60.2 57.2 69.3 ns ns
Chen et al. 2007 16
New 
Zealand 
white 
rabbits
4 and 12 
weeks
0.5nmol/
mg 
DBM 
rhBMP-
2 DBM empty DBM
rhBMP
2-h 
instead 
of 
rhBMP-
2
mandibu
lar 
defects 
critical 
size
healing 
percentag
e (%) 4 
weeks 60 30 50 80 s ns s (neg.)
new 
bone 
formati
on (%) 
12 
weeks 29 N/A 19 45 s s
Cochran et 
al. 1997 12
foxhoun
d dogs
4-12 
weeks
0.2mg/m
l rhBMP-
2
collagen 
or 
PLGA
no 
BMP-2
peri-
implant 
defects 
(circular
)
bone fill 
12 weeks 
(mm) 3.7mm 2.3 s
placement of a 
membrane had 
a positive 
effect on bone 
fill
Table 2. BMP-2 animals. 
Cochran et 
al. 1999 6
America
n 
foxhoun
ds
4 and 12 
weeks
0.2mg/m
l collagen
collage
n
± 
ePTFE 
membr
ane
rential 
peri-
implant 
defects
BIC 
(4weeks) 20 7 s
bone 
area (4 
weeks) 
mm2 6.99 2.45 s s
BIC (12 
weeks) 31 16 s
bone 
area (12 
weeks) 
mm2 7.5 4.7 s s
% bone 
fill 4-12 
weeks
25.7%-
46.7%
18.5-
34% ns
Cowan et 
al. 2007
Sprague-
Dawley
0-12 
weeks
30-
240ng/m
m3 PLGA
PLGA 
carrier
5mm 
critical 
size rat 
calvaria
newly 
formed 
bone (%) 
12 weeks 76-96 25 s
acquired from 
figure
Hong et al. 1998 ?
japanese 
white 
rabbits
4, 7, 14, 
21 days
0.1-1ug 
rhBMP-
2
PBS or 
gelatin 
hydrogel
PBS or 
gelatin 
hydrog
el
skull 
defects 
(6mm 
diameter
)
bone 
mineral 
density 
(21 days) 
mg/mm2 84-91 57-58 s
not all values 
indicated
Hou et al. 2007 40
New 
Zealand 
white 
rabbits
8 and 16 
weeks
200ug 
BMP2 coral
MSC + 
coral + 
bmp2 coral
autogra
ft
15 mm 
critical 
size 
skull 
defect
radioopaci
ty 
(16weeks) 
% 50% 78% 20% 85% s ns
circumfe
fluoresc
ence 
examin
ation 
(distanc
e 
betwee 6 10.2 13.5 s
s 
(negati
ve in 
favor 
of 
positiv
e 
Jones et al. 2006 12
america
n 
foxhoun
ds
4 and 12 
weeks 4mg/ml PLGA PLGA
± 
ePTFE 
membr
ane
circumfe
rential 
peri-
implant 
defects
% fill(4 
weeks) 24.26 14.46 s
% fill 
(12 
weeks) 42.76 36.81 ns
cranial 
defects 
9mm 
critical 
size
BIC 
(4weeks) 21.93 3.6 s
BIC (12 
weeks) 33.22 23.05 ns
Area (4 
weeks) 3.26 2.06 s
Area 
(12 
weeks) 5.24 3.88 ns
Jovanovic 
et al. 2007 7
hound 
dogs
12 
weeks
0.2mg/m
l
BMP + 
ACS
BMP + 
ACS + 
PTFE 
(w/ or 
w/o 
titaniu
m)
PTFE 
(w/ 
titaniu
m) w/ 
or w/o 
ACS
ACS or 
no 
treatme
nt
chronic 
saddle 
type 
defects bone fill 101% 101% 92% 60% equal
positiv
e
positiv
e
bone 
density 56% 34% 50% 57%
positiv
e
positiv
e
positiv
e
BMP + ACS + 
GBR: 
persistent 
seroma; often 
wound failure
Jung et al. 2005 16
New 
Zealand 
white 
rabbits 4 weeks 15ug
BMP + 
Fibrin
BMP + 
PRP Fibrin PRP empty
6 mm 
critical 
size 
skull 
defect 
skull
newly 
formed 
bone (%) 59.9 63.1 28.4 34.5 23.4 ns s s s
 
Kamakura 
et al. 2004
Wistar 
rats
4 and 8 
weeks
octacalci
um 
phosphat
e 10ug 
bmp
octacalci
um 
phosphat
e 1ug 
bmp
octacal
cium 
phosph
ate empty
new bone 
(4 weeks) 
% 44.1 42.1 17.8 10.3 ns s s
new 
bone (8 
weeks) 
% 68.4 59.2 30.5 11.1 ns s s
Kenley et 
al. 1994
Long-
Evans 
rats 3 weeks
30ug 
rhBMP-
2
30ugrhB
MP2 + 
Carrier
10ugrh
BMP2 
+ 
Carrier Carrier
8 mm 
critical 
size 
skull 
defect
new bone 
area 
(mm2) 1.3-2.2
1-
2.4mm
2
0.1-
0.5m
m2 s
sign. 
nur für 
30ug 
BMP
radioop
acity %
79-
92%
56-
84%
10-
24%
carrier and 
dose 
dependent 
results
Lee et al. 2003 24
new 
Zealand 
white 
rabbits
4 and 8 
weeks
5ug / 
membra
ne
PLLA/T
CP 
membra
ne
PLLA/
TCP 
membr
ane
denuded 
rabbit 
skull
bone area 
(%) 4 
weeks 15.9±3.7
6.1±4.
6 s
bone 
height 
(%) 4 
weeks
72.4±1
7.4
36.1±2
0.3 s
bone area 
(%) 8 
weeks 35.4±10
8.2±2.
6 s
bone 
height 
(%) 8 
weeks
87.3±1
4.5
36.3±1
3.8 s
Linde et al. 1995 27
Sprague-
Dawley
12 and 
24 days
0.1mg/m
l 
 ePTFE 
membra
ne + 
copolym
eric 
glycolid
e/lactide 
carrier + 
BMP-2
copoly
meric 
glycoli
de/lacti
de 
carrier 
+ BMP-
2
ePTFE 
membr
ane empty
5 mm 
critical 
size 
defect in 
mandibl
es
bone 
union 12 
days 4 5 1.9 0.4 ns s s
bone 
union 
24 days 4.8 4.2 2 0.6 ns s s
individual 
scoring system
Liu et al. 2007 18
mini-
pigs
1-3 
weeks
5-
10ng/ml
BMP-2 
coating 
of 
implants 
(incorpo
rated or 
adsorbe
d no bmp
implants 
placed 
in 
maxilla
bone 
deposition 
in bone 
chambers 
(total bone 
%) 1week 1-10% 4%
depend
ing on 
time 
and 
coating 
proced
ure
negativ
e for 
total 
bone at 
3 
weeks
acquired from 
figure
Lopez-
Lacomba et 
al. 2006
New 
Zealand 
white 
rabbits 5 weeks
BMP-2 
coated 
implant
Ti-
implant
tibia 
implant 
placeme
nt
removal 
torque N 
.cm 60 37 s
acquired from 
figure
Lutolf et al. 2003 25 rats 5 weeks
0.05mg/
ml
PEG 
MMP 
sensitive
PEG  
MMP 
insensit
ive + 
BMP
PEG 
MMP 
sensitiv
e with 
BMP
collage
n + 
BMP
8mm 
critical 
size rat 
calvaria
bone 
volume 
(mm3) 4 6 21 20
positiv
e
acquired from 
figure
MMP sensitive 
+ BMP 
necessary for 
equal results as 
collagen + BMP
Carrier: blood, alginate, ICBM, 
hydroxypropylcellulose (HPMC)
s only for 
ICBM 0 and 
10ug versus 
other carriers
 bone 
Mao et al. 1998 48 rabbits
4 and 8 
weeks ?
rhBMP-
2-
collagen-
chitin
collage
n-chitin empty
15x15m
m rabbit 
calvaria
regenerati
on/defect 
(%) 8 
weeks 59% 41% 22%
posititv
e
positiv
e
Marden et 
al. 1994 >10
Long-
Evans 
rats 1 week
6.5ug 
bmp2 + 
insolubl
e 
collagen
ous bone 
matrix 
(ICBM)
2.2ug 
BMP2 + 
ICBM ICBM DBM
8 mm 
critical 
size 
skull 
defect
new 
calcified 
tissue 
(mm2) 1 
weeks ns ns ns
2 weeks
new 
calcified 
tissue 
(mm2) 2 
weeks 3.5 2.5 1.2 0.2 s s s
3 weeks
new 
calcified 
tissue 
(mm2) 3 
weeks 3.3 3.6 2 0.5 ns s s
acquired from 
figure
Matin et al. 2001
Wistar 
rats
14-84 
days
0.4mg/m
l
PLGS-
GS
PLGS-
GS
tooth 
extractio
n 
sockets
total bone 
area 
mm2(exist
ing + new 
bone) 14-
56 days 1.8-2.3 1.4-2.1 s
alveolar 
bone 
height
s (14, 
28, and 
56 
days)
ns (84 
days)
acquired from 
figure
Matin et al. 2003 8
Wistar 
rats 90 days ?
PLGS-
GS
PLGS-
GS
no 
graftin
g 
materia
l
immedia
te 
implants
; peri-
implant 
bone 
regenera
tion
regenerate
d bone 
height 
(microCT) 30% ? ? s s
Meraw et 
al. 2000 5
foxhoun
ds 12
1.2pg 
TGF-
BB, 1.2 
pg 
bFGF, 
0.5 pg 
BMP-2, 
0.6 pg 
PDGF
calcium
phosphat
e
calciu
mphos
phate empty
peri-
implant 
circumfe
rential 
defects
newly 
formed 
bone
76.8 ± 
3.7%
67.4% 
± 6.2
64 ± 
4.2% s s BIC
77.4 ± 
7.2%
59.7 ± 
12.6%
54.8 ± 
12.3% s s
Miki et al. 2000 24
Wistar 
rats
2 and 4 
weeks
10ug/dis
c
FD-
PGLA/
HA/rhB
MP-2
FD-
PGLA/
HA/
8 mm 
critical 
size 
skull 
defect
bone 
density 
(2weeks) 
(mmA1) 1.03 0.995 ns
bone 
density 
(4week
s) 
(mmA1
) 1.3 0.6 s
 
 
Mukherjee 
et al. 2003 rats
9 and 18 
weeks
40ug 
BMP-2
chitosan-
glutamat
e
chitosa
n-
glutam
ate + 
bone 
marrow
chitosa
n-
glutam
ate + 
osteobl
asts
chitosa
n-
glutam
ate empty
8mm 
critical 
size rat 
calvaria
bone 
mineral 
density 
(g/cm2) 9-
18weews 0.06-0.07
0.04-
0.04
0.07-
0.05
0.05-
0.06
0.03-
0.02
positiv
e
negativ
e
positiv
e
postitiv
e
Nagao et al. 2002 12
beagle 
dogs
2, 4, 8, 
12 
weeks
0.4mg/m
l
PLGS/P
GS
PLGS/
PGS
mandibu
lar 
defects 
critical 
size
quantitativ
e ct scan: 
bone 
mineral 
density 
(mg/cm3) 
2-12 
weeks 376-716
not 
indicat
ed
posititv
e
Nevins et 
al. 1996 6
Alpine-
Saanen 
goats
4, 8, and 
12 
weeks
0.43mg/
ml ACS ACS Sinuslift
radioopaci
ty
increasing 
radioopac
ity for 
BMP-2
decrea
sing 
radioo
pacity 
w/o 
BMP-2
positiv
e
Pratt et al. 2004
Sprague-
Dawley 3 weeks
5ug / 
implant
hydrogel 
+ BMP 
(bound), 
plasma 
sensitive
hydrog
el + 
bmp 
(not 
bound) 
plasma 
sensitiv
e
hydrog
el + 
bmp 
(not 
bound), 
not 
plasma 
sensitiv
e
hydrog
el 
plasma 
sensitiv
e
8 mm 
critical 
size 
skull 
defect 
skull
radiologic 
area ne 
bone/bone 
defect 
area (%) 94% 73%
ca. 
10%
ca. 
18% s s s
Salata et al. 2007 12
mongrel 
dogs
4 and 12 
weeks
? 
(Regenaf
ilTM) collagen
collage
n
autoge
nous 
bone empty
peri-
implant 
defect
BIC 4 
weeks 17-24 17-30 14-31 25-35 ns ns ns
BIC 12 
weeks 23-31 15-18 18-26
12-
30% ns ns ns
Schmoekel 
et al. 2004a ?
Sprague-
Dawley 
rats 21 days
1ug TG-
plBMP-
2 fibrin fibrin
1ug 
wildtyp
e BMP-
2 in 
fibrin
calvarial 
defects; 
critical 
size 
(8mm)
mean area 
of defect 
filled (x-
ray) 81% n/a 46% s s
8
new 
Zealand 
white 
rabbits 28 days
5ug TG-
plBMP-
2 fibrin fibrin empty
calvarial 
defects; 
non 
critical 
size 
(6mm)
mean area 
of defect 
filled (x-
ray) 47% 33% 30% s s
15ug TG-
plBMP-
2 73.00% 33% 30% s s
Schmoekel 
et al. 2004b
Sprague-
Dawley 3 weeks
1, 5, 
20ug 
BMP
fibrin + 
bmp
fibrin + 
1.3ug 
heparin fibrin empty
critical 
size 
defects 
skull 
8mm
bone 
regenerati
on defect 
closure (ct 
scan) % 74-98 13.3 8 s s
 
Schrier et 
al. 2001 30
new 
Zealand 
white 
rabbits
90ug 
BMP-2
CMC+P
LGA 
microsp
heres
CMC+
PLGA 
micros
pheres CMC
calvarial 
defects 
(7.9mm)
bone 
growth 
(scoring) 2.8 0.6 1 s s
aquired from 
figure
Sigurdsson 
et al. 1997 5
beagle 
dogs
16 
weeks
0.43mg/
ml 
rhBMP-
2 ACS ACS
peri-
implant 
bone 
regenera
tion
defect 
osseointeg
ration % 19.1 8.2 ns
bone 
regener
ation 
(area)
6.1mm
2
0.2mm
2 ns
osseointeg
ration 
within 
reg. bone 
% 29.1 65.3 s (neg.)
bone 
regener
ation 
(height) 4.2mm 0.5mm s
alveolar 
osseointeg
ration (%) 67.1 68.1 ns
Sykaras et 
al. 2001 14
foxhoun
ds
2, 4, 8, 
12 
weeks
0.4mg/m
l
ACS + 
BMP 
ACS + 
BMP + 
implant
ACS + 
implant ACS
defects 
in 
hollow 
cylinder
bone fill 
(%) 2 
weeks 0.95 1.92 ns
BIC 
(%) 2 
weeks 5 4 nsbone fill 
(%) 
4weeks 23 6 s
BIC 
(%) 
4weeks 14 5 ns
bone fill 
(%) 8 
weeks 21 8 s
BIC 
(%) 8 
weeks 19 7 s
bone fill 
(%)  12 
weeks 31 24 ns
BIC 
(%)  12 
weeks 44 21 s
radiographic 
results: 
Cochran 1997
Takahashi 
et al. 2007 6
monkey
s
12 
weeks
5ug / 
site
gelatin 
hydrogel
IBM 
(bone 
mineral
) + 
bmp
gelatin 
hydrog
el PBS
6 mm 
critical 
size 
skull 
defect 
skull
bone 
mineral 
density 
(mg/cm2) 189 99 129 80 s s
Takeishi et 
al. 2001 36
Wistar 
rats
2, 4, and 
8 weeks
5ug 
BMP
PGS + 
ePTFE 
mold
PGS + 
bmp2
ePTFE 
alone
non 
critical 
size 
bone 
defect 
(skull)
bone 
augmentat
ion (%) (8 
weeks); 
cave 
thickness! 100%
ca. 
70%
ca. 
70% s s
acquired from 
figure
Weber et al. 2002 rats 33 days
12ug 
bmp
bmp + 
foamsph
eres
bmp + 
gelatin
e 
hydrog
el
untreat
ed
thicknes
s of 
calvarial 
bone
thickness 
of 
calvarial 
bone 
(mm) 3 1.5 0.9 s s
Wikesjö et 
al. 1999 8
beagle 
dogs 8 weeks
0.05, 
0.1, 
0.2mg/m
l ACS ACS
critical 
size, 
alveolar 
periodon
tal 
defects
bone 
regenerati
on  (%) 86-96% ?
positiv
e
no statistical 
analysis
 vertical 
Wikesjö et 
al. 2002 6
hound 
labrador 
dogs
16 
weeks
0.4mg/m
l rhBMP-
2
calcium
phosphat
e cement 
(alpha-
BSM)
calciu
mphos
phate 
cement 
(alpha-
BSM)
ridge 
augment
ation 
critical 
size 
5mm 
peri-
implant 
defects
new bone 
density 
(%) 55.1 67.7
negativ
e
new 
BIC 
(%) 26.9 24.6
positiv
e
no statistical 
analysis
new bone 
area 
(mm2) 8.5 0.5
positiv
e
vertical 
bone 
growth 
(mm) 4.9 0.4
positiv
e
Wikesjö et 
al. 2003 9
beagle 
dogs
8, 24 
weeks
0.2mg/m
l
hyaluron
e carrier 
+ PGA-
TMC 
membra
ne
hyaluro
ne 
carrier 
+ PGA-
TMC 
membr
ane
critical 
size, 
alveolar 
periodon
tal 
defects
bone 
height 
(mm) 8 
weeks 3.8±1.3
0.7±0.
5 s
bone 
height 
(mm) 
24week
s
4.6±0.
8
2.1±0.
4 s
Woo et al. 2001 15
New 
Zealand 
white 
rabbits
up to 6 
weeks
0.5mg/m
l PLGA PLGA
no 
treatme
nt
bone 
regenerati
on/defect 
(%) 75-79% 45% 0% s s
Würzler et 
al. 1998 34
Long-
Evans 
rats 21 days
25ug 
rhBMP-
2
collagen
ous bone 
matrix
collage
nous 
bone 
matrix empty
skull 
defects 
(3mm)
newly 
formed 
bone 
(irradiatio
n after 2 
days) 34% 7% 5% s s
newly 
formed 
bone 
(irradiatio
n after 7 
days) 68% 32% s
35ug 
rhBMP-
2 77% 7% 5% s s
Zellin & 
Linde 1997 46
Sprague-
Dawley
12 and 
24 days
1 and 
8ug 
BMP-2
collagen 
or 
PLA/PG
A 
±ePTFE 
membra
ne
ePTFE 
membr
ane
5mm 
transoss
eous 
mandibu
la 
(critical 
size)
bone 
healing 
(%) of 
defect 12 
days 7-100% 1 s
12 days 
area of 
newly 
formed 
bone 1.9-8.1 1.8
s 
(except
: BMP 
PLA/P
GA 1 
and 
8ug)
bone 
healing 
(%) of 
defect 24 
days 58-100 52
s 
(except
: 
membr
ane 
BMP 
ACS 1 
and 
8ug)
24 
days; 
area of 
newly 
formed 
bone 1.8-5.1 2
s 
(only: 
BMP 
8ug 
ACS 
or 
PLA/P
GA 
withou
t 
membr
ane)
membrane 
decreased bone 
regeneration
excluded:
Becker et 
al. 2006
excluded (only 
2 animals)
Fiorellini et 
al. 2001
excluded (only 
2 animals)
Seol et al. 2006
excluded; only 
2 animals
Sigurdsson 
et al. 2001
excluded: no 
control
Tatakis et 
al. 2002
exclud (no 
negative/positi
ve control)
 
 
 
 
 
Table 3. BMP-7 animals. 
 
Author
year of 
publica
tion
numbe
r of 
animal
s animal species
follow-up 
period
applied 
dose
carrier 
system control 1 control 2 control 3
type of 
defect 
outcome 
measure
outcom
e test
outcom
e 
control 
1
outcom
e 
control 
2
effect 
of 
factor 
vs. 
contro
l 1
effect 
of 
factor 
vs. 
contro
l 2
outcome 
measure outcome test
outcom
e 
control 
1
outcom
e 
control 
2
outcom
e 
control 
3
effect 
of 
factor 
vs. 
control 
1
effect 
of 
factor 
vs. 
control 
2
effect 
of 
factor 
vs. 
control 
3 comments
Liu et al. 2006 28
New Zealand 
white rabbits
2-12 
weeks
1mg/ml 
rhOP-1
gelatin 
sponge
gelatin 
sponge
extraction 
sockets
ALP (U/mg 
tissue)  2-12 
weeks 2.3 to 51.3
1.2 to 
24.3 s
Ca (ug/mg 
tissue) 2-12 
weeks 5.6 to 29.3
1.0 to 
15.3 s
Margolin 
et al. 1998 15 chimpanzees
1 week to 
6.5 
months
0.25-
2.5mg 
rhOP-1
collagen 
matrix
natural 
bone 
mineral
collagen 
matrix
maxillary 
sinus 
augmenta
tion
new bone 
(%) 7.5 
months 46-57 47 34 ns ns
bone mineral 
density 
increase 
(mg/cc) 6.5 
months 280-415 383 293 ns ns
data partially 
acquired 
from figures
McAllister 
et al. 1998 15 chimpanzees
7.5 
months
0.25-
2.5mg 
rhOP-1
collagen 
matrix
natural 
bone 
mineral
collagen 
matrix
maxillary 
sinus 
augmenta
tion
new bone 
(%) 6.5 
months 47-57 47 29 ns
s for 
0.6 
and 
2.5mg 
OP-1
bone mineral 
density  
(mg/ml) 6.5 
months 397-486 783 344
s 
(negativ
e)
Mhawi et 
al. 2007 14
Sprague-
Dawley rats
4 and 8 
weeks
0.25cm3 
OP-1
collagen 
carrier empty
calvarial 
defects 
(5mm)
new bone 4-
8 weeks 54-65 35-53 s
14
Sprague-
Dawley rats
4 and 8 
weeks
0.25cm3 
OP-1
collagen 
carrier
AccellDB
M100 
calvarial 
defects 
(5mm)
new bone 4-
8 weeks 62-69 50-57 ns
Ripamonti 
et al. 1996 6 baboons 30 days
0.1-2.5mg 
rhOP-1
collagen 
matrix
baboon 
collageno
us matrix
calvarial 
defects 
(2.5cm)
new bone 
(%) (day 30) 23-29 9 s
new bone 
(mm2) 30 
days) 100-300 20 s
data partially 
acquired 
from figures
6 baboons 90 days
0.1-2.5mg 
rhOP-1
collagen 
matrix
baboon 
collageno
us matrix
new bone 
(%) (day 90) 47-55 29 s
new bone 
(mm2) 90 
days) 55-100 25 ns
data partially 
acquired 
from figures
10 baboons
15-365 
days
0.1-2.5mg 
rhOP-1
collagen 
matrix
bovine 
collageno
us matrix
new bone 
(%) (day 
365) 57-65 37 s
new bone 
(mm2) 365 
days) 65-100 25 s
data partially 
acquired 
from figures
Ripamonti 
et al. 2001 12 baboons
3-12 
months
0.5mg 
rhOP-1 HA
0.1mg 
rhOP-1 HA
calvarial 
defects 
(2.5cm)
bone 
volume (%) 
(1 month) 24 25 1 ? sbone 
volume (%) 
(3 month) 55 48 25 ns s
bone 
volume (%) 
(12 month) 51 50 22 ns s
Springer et 
al. 2005 17 mini-pigs 4 months
1mg rhOP
1
collagen 
+ CMC
autologou
s bone 
graft 
(iliac) empty
no 
treatment
calvarial 
defects 
(2x4cm)
bone density 
(%) 61 62 ? 58-61 ns ? ns
bone volume 
(cm3) 8.5 7.5 5
11-12 
cm3 N/A N/A ns
 Terheyden 
et al. 1999 5 mini-pigs 6 months
420ug 
rhOP-1 BioOss BioOss
maxillary 
sinus 
augmenta
tion + 
implant 
placement
BIC (6 
months) 80 38.6 s
excluded:
Allegrini 
et al. 2004
excluded: 
type of BMP 
not indicated
Girard et 
al. 2007
excluded: no 
comparison ± 
BMP-7
Ripamonti 2005
excluded: no 
values given 
for control 
group
Terheyden 
et al. 1997
only 
descriptive 
results
Terheyden 
et al. 2001
exluded: 
same study as 
1999
Table 4. GDF-5 animals. 
Author
year of 
publication
number 
of 
animals
animal 
species
follow-up 
period
applied 
dose
carrier 
system
control 
1
control 
2
control 
3
control 
4
control 
5
type of 
defect 
outcome 
measure
outcome 
test
outcome 
control 
1
outcome 
control 
2
outcome 
control 
3
outcome 
control 
4
outcome 
control 
5
effect of 
factor 
vs. 
control 
1
effect of 
factor 
vs. 
control 
2
effect of 
factor 
vs. 
control 
3
effect of 
factor 
vs. 
control 
4
effect of 
factor 
vs. 
control 
5 comments
Poehling et al. 2006 20
Sprague-
Dawley 6 weeks
500ugrhG
DF5/g 
TCP 
(=MD05) TCP
bovine 
bone 
mineral 
(BBM)
BBM + 
collagen
BBM + 
syntheti
c 
peptide TCP
sham-
operate
d
6mm 
calvarial 
defects
new 
bone  
(%) 51 10 3.7 11.6
10.2-
11.8 23.3 s s s s s
excluded:
Simank et al. 2006
exluded: orthopedic 
implants (femur)
Yoshimoto et al. 2006
excluded: only 
descriptive results for 
bone regeneration
 
Table 5. PDGF animals. 
 
Author
year of 
publicati
on
number 
of 
animals animals
follow-
up 
period 
(weeks) applied dose
carrier 
system control 1 control 2
type of 
defect outcome measure
outcome 
test
outcome 
control 1
outcome 
control 2
effect of 
factor vs. 
control 1
effect of 
factor vs. 
control 2
outcome 
measure
outcome 
test
outcome 
control 1
outcome 
control 2
effect of 
factor 
vs. 
control 1
effect of 
factor 
vs. 
control 2 comments
Lee et al. 2001 8
New 
Zealand 
white 
rabbits 4
500ng/mem
brane
PLLA-
TCP 
membrane
PLLA-
TCP 
membra
ne
monocortical 
calvarial 
defects 
(20mm)
newly formed 
bone
27.4 ± 
6.4%
13.0 ± 
4.8% s
Lee et al. 2000 24
Sprague 
Dawley 
rats 2 and 8
PDGF 
200ng / 
10x10x1mm 
sponge
chitosan/T
CP
chitosan/
TCP empty
critical size 
defect 
craniotomie 
(8mm 
diameter)
newly formed 
bone (2 w) (x 
1000 um2)
499.92 ± 
76.02
230.83 ± 
42.73
114.22 ± 
47.73 s s
Lioubavina-
Hack et al. 2005a 55
albino 
rats of 
Wistar 
strain 8
1200ug/ml 
rhPDGF/IG
F
methylcell
ulose gel + 
teflon 
capsule
methylc
ellulose 
gel + 
teflon 
capsule
teflon 
capsule
mandibular 
ramus 
denuded 
bone
newly formed 
bone 6.30% 5.5 29.9 ns s (neg)
without periosteum 
on bone
600ug/ml 
rhPDGF/IG
F
methylcell
ulose gel + 
teflon 
capsule
methylc
ellulose 
gel + 
teflon 
capsule
teflon 
capsule 6.1 5.5 29.9 ns s (neg)
no statistical 
analysis (low 
number of animals)
150ug/ml 
rhPDGF/IG
F
methylcell
ulose gel + 
teflon 
capsule
methylc
ellulose 
gel + 
teflon 
capsule
teflon 
capsule 5.6 5.5 29.9 ns s (neg)
Lioubavina-
Hack et al. 2005a
albino 
rats of 
Wistar 
strain 8
1200ug/ml 
rhPDGF/IG
F
methylcell
ulose gel + 
teflon 
capsule
methylc
ellulose 
gel + 
teflon 
capsule
teflon 
capsule
mandibular 
ramus 
denuded 
bone
newly formed 
bone 19.60% 21 39.7 ns ns
600ug/ml 
rhPDGF/IG
F
methylcell
ulose gel + 
teflon 
capsule
methylc
ellulose 
gel + 
teflon 
capsule
teflon 
capsule 18.7 21 39.7 ns ns
150ug/ml 
rhPDGF/IG
F
methylcell
ulose gel + 
teflon 
capsule
methylc
ellulose 
gel + 
teflon 
capsule
teflon 
capsule 17.9 21 39.7 ns ns
Lioubavina-
Hack et al. 2005b 8
albino 
rats of 
Wistar 
strain
12 and 
20 20ug PDGF
BioOss + 
autologous 
blood 
Teflon 
capsule
BioOss 
+ 
autologo
us blood 
Teflon 
capsule
denuded 
mandibibula
r ramus
newly formed 
bone (12w)
6.7% ± 
2.3
20.8% ± 
10.0 neg
newly formed 
bone (20w)
23.0% ± 
12.3
26.0% ± 
15.0 neg
 Marden et al. 1993 144
Long-
Evans 
rats 28 days
0-200ug 
PDGF
ICBM 
(insoluble 
rat 
collagenou
s bone 
matrix) 0-
150ug 
osteogenin 
(BMP2, -3, 
-7)
critical size 
defect 
craniotomie 
(8mm 
diameter) radioopacity (%) 5-79% 18-99%
sign. less 
bone 
regeneratio
n with 
PDGF negative
newly formed 
bone 20 days 
(mm2) 0.7-4.3 1.1-5.7
sign. 
less 
bone 
regenera
tion with 
PDGF negative
Meraw et al. 2000 5
foxhoun
ds 12
1.2pg TGF-
BB, 1.2 pg 
bFGF, 0.5 
pg BMP-2, 
0.6 pg 
PDGF
calciumph
osphate
calcium
phosphat
e empty
peri-implant 
circumferent
ial defects
newly formed 
bone
76.8 ± 
3.7%
67.4% ± 
6.2
64 ± 
4.2% s s BIC
77.4 ± 
7.2%
59.7 ± 
12.6%
54.8 ± 
12.3% s s
Simion et al. 2006 6
foxhoun
ds 16
rhPDGF 
(dosis ?)
deproteiniz
ed bovine 
bone block 
(DBBB)
rhPDGF 
+ DBBB 
+ 
collagen 
membra
ne
DBBB + 
collagen 
membra
ne
vertical 
ridge 
augmentatio
n
uneventful 
healing rate (%) 75% 75% 25%
better results w/o 
collagen membrane
Stefani et al. 2000 3
mongrel 
dogs 3
50ug/ml 
rhPDGF + 
rhIGF-1
methylcell
ulose gels 
(4.4%)
methylc
ellulose 
gels 
(4.4%)
immediate 
implants in 
fresh 
extraction 
sockets
newly formed 
bone 3 weeks
46.3 ± 
5.9%
51.4 ± 
12.1% ns BIC
17.2 ± 
13.8%
24.4 ± 
13.7 s
with periosteum on 
bone
3 8
50ug/ml 
rhPDGF + 
rhIGF-1
methylcell
ulose gels 
(4.4%)
methylc
ellulose 
gels 
(4.4%)
immediate 
implants in 
fresh 
extraction 
sockets
newly formed 
bone 8 weeks
44.9 ± 
20.7%
53.0 ± 
25.0% ns BIC
16.9 ± 
16.1%
24 ± 
21.9% ns
2 12
50ug/ml 
rhPDGF + 
rhIGF-1
methylcell
ulose gels 
(4.4%)
methylc
ellulose 
gels 
(4.4%)
immediate 
implants in 
fresh 
extraction 
sockets
newly formed 
bone 12 weeks
45.0 ± 
13.2%
48.4 ± 
10.2% ns BIC
16.9 ± 
13.9%
20.5 ± 
7.2% ns
Vikjar et al. 1997 16
New 
Zealand 
white 
rabbits 8 50ug/ml
methylcell
ulose gels 
(4.4%)
methylc
ellulose 
gels 
(4.4%)
bicortical; 
critical size; 
rabbit skull
newly formed 
bone within 
defects
51.8 +- 
7.1%
30.5 +- 
3.3% s
mineralized 
tissue
7.19mm
2 +- 
1.24
3.35mm
2 +- 
0.54 s
excluded:
Chung et al. 1997
excluded (no 
statistical analyis; 
just descriptive x 
mm remaining 
defect size)
Im et al. 2003
excluded: no 
measurements for 
critical size defects
Lee et al. 2002
excluded (no 
measurements; just 
descriptive results)
Park et al. 1998
excluded (no 
measurements; just 
descriptive results)
Table 6. PTH animals. 
 
Author
year of 
publication
number of 
animals animals
follow-up 
period 
(weeks) applied dose
carrier 
system control 1 control 2 control 3 type of defect 
outcome 
measure outcome test
outcome 
control 1
outcome 
control 2
outcome 
control 3 
effect of 
factor vs. 
control 1
effect of 
factor vs. 
control 2
effect of 
factor vs 
control 3 comments
Andreassen & 
Cacciafesta 2004 44 Wistar rats 35 days
60ug/kg 
PTH(1-34)
saline, rat 
serum
saline, rat 
serum
critical size defect 
calvarial bone 
(5mm) with 
ePTFE bicortical
tissue dry 
weight 
within 
defect (mg) 5.3 2.7 s
ash weight 
(mg) 3 1.3 s
mechanical 
loading 
(ultimate 
stiffness) 
N/mm 96 40 s
Jung et al. 2007a 16 rabbits 8 weeks
20ug/g PTH 
+ 350ug/g 
RGD
PEG + 
HA/TCP empty
PEG + 
HA/TCP
titanium cylinders 
rabbit skull
newly 
formed bone
51.5% ± 
22.6
23.2% ± 
10.1
34.3% ± 
22.5 s s
100ug/g 
PTH
53.5% ± 
22.7 s s
Jung et al. 2007b 6 foxhounds
4 and 12 
weeks
20ug/g PTH 
+ 350ug/g 
RGD PEG PEG
autogenous 
bone empty
peri-implant 
defects
newly 
formed bone 
4 weeks 41.7 ± 1.8% 26.6 ± 4.1% 43.9 ± 4.5% 28.9 ± 1.5% s ns s
newly 
formed bone 
12 weeks 49.4 ± 7.0% 39.3 ± 5.7% 50.5 ± 3.4% 38.7 ± 1.9% s ns s
Skriptiz et al. 2000 38
Sprague-
Dawley rats 2-6 weeks
60ug/kg 
PTH(1-34)
saline, rat 
serum
saline, rat 
serum
titanium cylinders 
rabbit skull
bone density 
(2 weeks) 48% 44% s
excluded: 60% 24% s
Cornish et al. 1995
excluded: reports 
bone resorption for 
PTH; but no values 
given for test/control 
sites
